文献速递淋巴瘤

REALYSA研究:弥漫性大B细胞淋巴瘤真实世界数据的质量与利用挑战

Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.
PubMed 文献 · Blood Adv · 2024-01-01

REALYSA是一项2018年启动的法国前瞻性非干预性多中心淋巴瘤队列,本研究对645例一线接受免疫化疗的弥漫性大B细胞淋巴瘤患者进行概念验证分析,通过多步核查产生3589条质疑,数据缺失率低于4%,1年无事件生存率和总生存率分别为77.9%和90.0%,中位随访9.9个月,按试验主要入组标准筛选后REALYSA患者与POLARIX和SENIOR试验标准治疗组结局似乎相当。

要点

  • REALYSA队列经多步核查产生3589条质疑,数据缺失率低于4%。
  • 645例患者中R-CHOP占75%,减量R-CHOP占13%。
  • 1年无事件生存率77.9%,总生存率90.0%,中位随访9.9个月。

核心结论

  • REALYSA通过严格的数据核查流程提供高质量真实世界数据,可作为众多科学研究的平台。

研究设计与样本

  • REALYSA是一项2018年启动的法国前瞻性非干预性多中心队列,纳入新诊断淋巴瘤患者。
  • 本分析纳入2021年3月31日前入组、接受免疫化疗的645例一线弥漫性大B细胞淋巴瘤患者。

主要发现

  • 分析人群产生3589条质疑,数据完整性高,缺失数据低于4%。
  • 中位年龄66岁,多为晚期疾病和高国际预后指数评分。
  • 治疗以R-CHOP为主(75%),减量R-CHOP占13%。
  • 估计1年无事件生存率为77.9%,1年总生存率为90.0%,中位随访9.9个月。
  • 应用试验主要入组标准(年龄、体能状态、国际预后指数)后,REALYSA患者与POLARIX标准治疗组1年无进展生存率均为79.8%,与SENIOR标准治疗组1年无事件生存率分别为64.5%和60.0%,结局似乎相当。

关键数值与推荐

  • 数据缺失率低于4%,共产生3589条质疑。
  • R-CHOP占75%,减量R-CHOP占13%。
  • 1年无事件生存率77.9%,1年总生存率90.0%,中位随访9.9个月。
  • REALYSA与POLARIX标准治疗组1年无进展生存率均为79.8%。
  • REALYSA与SENIOR标准治疗组1年无事件生存率分别为64.5%和60.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Real-world data (RWD) are essential to complement clinical trial (CT) data, but major challenges remain, such as data quality. REal world dAta in LYmphoma and Survival in Adults (REALYSA) is a prospective noninterventional multicentric cohort started in 2018 that included patients newly diagnosed with lymphoma in France. Herein is a proof-of-concept analysis on patients with first-line diffuse large B-cell lymphoma (DLBCL) to (1) evaluate the capacity of the cohort to provide robust data through a multistep validation process; (2) assess the consistency of the results; and (3) conduct an exploratory transportability assessment of 2 recent phase 3 CTs (POLARIX and SENIOR). The analysis population comprised 645 patients with DLBCL included before 31 March 2021 who received immunochemotherapy and for whom 3589 queries were generated, resulting in high data completeness (<4% missing data). Median age was 66 years, with mostly advanced-stage disease and high international prognostic index (IPI) score. Treatments were mostly rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP 75%) and reduced dose R-CHOP (13%). Estimated 1-year event-free survival (EFS) and overall survival rates were 77.9% and 90.0%, respectively (median follow-up, 9.9 months). Regarding transportability, when applying the CT's main inclusion criteria (age, performance status, and IPI), outcomes seemed comparable between patients in REALYSA and standard arms of POLARIX (1-year progression-free survival 79.8% vs 79.8%) and SENIOR (1-year EFS, 64.5% vs 60.0%). With its rigorous data validation process, REALYSA provides high-quality RWD, thus constituting a platform for numerous scientific purposes. The REALYSA study was registered at www.clinicaltrials.gov as #NCT03869619.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ghesquières H, Cherblanc F, Belot A, et al. Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort. Blood Adv. 2024. PMID: 37874913. doi:10.1182/bloodadvances.2023010798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。